<DOC>
	<DOCNO>NCT00749567</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity combination erlotinib bevacizumab patient locally advanced metastatic , non-squamous non-small cell lung cancer , progress first line treatment . Pretreatment one two agent would exclude patient study , order evaluate whether combination two biologic agent could reverse tumor resistance .</brief_summary>
	<brief_title>Combination Erlotinib Bevacizumab Second-line Treatment Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>A randomized , placebo-controlled phase III trial erlotinib versus placebo , demonstrate therapy tyrosine kinase inhibitor ( TKI ) prolongs survival first second line therapy patient advance NSCLC . Moreover , addition bevacizumab , monoclonal antibody Vascular Endothelial Growth Factor bevacizumab ( VEGF ) , systemic chemotherapy , improve response rate time tumor progression two trial . Early data phase I/II trial examine combination two biological agent pre-treated patient non-squamous NSCLC , show major pharmacokinetic interaction promise clinical activity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm , unresectable locally advanced ( stage IIIB pleural effusion ) and/or metastatic ( stage IV ) NSCLC Progression firstline therapy advanced/metastatic NSCLC Bidimensionally measurable disease ( included radiation field ) ECOG performance status 02 Life expectancy 6 month Adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit , AST ALT &lt; 2.5 time upper normal limit absence demonstrable liver metastasis , &lt; 5 time upper normal limit presence liver metastasis , adequate renal function ( serum creatinine &lt; 1.5 time upper normal limit ) , bone marrow ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) function Signed informed consent Central nervous system involvement ( unless patient previously irradiate clinically stable ) Presence centrally locate mass tumor mass close relation large vessel mass cavitation . Surgery radiation therapy within last 14 day study entry Active infection History lifethreatening hemoptysis / hematemesis , history thrombosis use anticoagulation therapy History significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction , ventricular arrhythmia ) stroke within previous 6 month uncontrolled hypertension Patients experimental treatment protocol History second primary malignancy ( basalcell skin carcinoma situ carcinoma cervix ) Psychiatric illness social situation would preclude study compliance Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>TKI 's</keyword>
	<keyword>Anti-VEGF</keyword>
</DOC>